Validation, Visualization, and Clinical Interpretation of Structural Variants

  • Structural variant (SV) analysis involves more than identifying deletions, insertions, duplications, inversions, translocations, and copy-number variations from sequencing data. The detected variants must be carefully validated, accurately visualized, and biologically interpreted before they can be used in research, clinical diagnosis, or animal breeding. Structural variants can affect large genomic regions, disrupt genes, alter gene dosage, modify regulatory elements, and change chromosome organization. However, sequencing errors, alignment problems, repetitive DNA, incomplete genome assemblies, and computational limitations can produce false-positive or inaccurate variant calls. Validation, visualization, and interpretation are therefore essential stages of a reliable structural variant analysis workflow.
  • Structural variant validation is the process of confirming that a computationally identified variant represents a genuine genomic alteration. Variant callers identify candidate structural variants using evidence such as discordant paired-end reads, split reads, sequencing depth, read orientation, and long-read alignments. However, a predicted variant may result from sequencing errors, mapping artefacts, reference genome limitations, or incorrect breakpoint identification. Validation evaluates the supporting evidence and, when necessary, uses independent experimental methods to confirm the variant. Important characteristics include variant type, genomic position, size, breakpoint accuracy, genotype, copy number, and consistency across sequencing technologies or analytical methods.
  • One approach to validation is read-level evidence inspection. Researchers examine sequencing reads supporting a predicted variant to determine whether the alignment patterns are consistent with the proposed genomic rearrangement. Split reads that cross a breakpoint provide direct evidence of a structural change, while discordant read pairs may indicate abnormal distances, orientations, or chromosome locations. Changes in sequencing depth can support deletions and duplications. Long reads spanning the breakpoint can provide particularly strong evidence because they may cover the complete altered region and its surrounding sequences. Read-level inspection is important for distinguishing genuine variants from alignment artefacts, especially in repetitive regions and segmental duplications.
  • A second approach involves comparing the results of multiple structural variant callers. Different algorithms use different detection strategies and may identify different subsets of variants. Short-read callers such as Manta, DELLY, LUMPY, and GRIDSS use combinations of paired-end, split-read, and other alignment evidence. Long-read callers such as Sniffles, cuteSV, and pbsv are designed to identify structural variants from long-read alignments. Copy-number tools such as CNVnator, Control-FREEC, and GATK gCNV provide additional evidence for copy-number changes. Comparing calls from different algorithms can increase confidence, particularly when independent methods identify similar genomic events. However, agreement between callers does not automatically establish biological validity because different tools may share similar limitations or rely on the same underlying sequencing data.
  • Variant comparison and benchmarking are important components of structural variant validation. Tools such as SURVIVOR and Truvari can compare structural variant call sets, merge similar calls, and evaluate differences between predicted and reference variants. Comparison requires appropriate thresholds for genomic distance, reciprocal overlap, variant size, and sequence similarity. Structural variants can be difficult to compare because different callers may report slightly different breakpoints or represent complex events in different ways. A deletion detected by two callers, for example, may have similar genomic boundaries but different reported sizes. Standardized comparison criteria help reduce inconsistent results and improve reproducibility.
  • Experimental validation provides additional evidence for important structural variants. Polymerase chain reaction (PCR) can be used to amplify regions surrounding a predicted breakpoint. If a deletion or insertion is present, the amplified fragment may differ in size from the corresponding fragment in a reference genotype. Breakpoint-specific PCR can provide evidence that two genomic regions have become joined through a rearrangement. Quantitative PCR (qPCR) and digital droplet PCR (ddPCR) can be used to estimate gene copy number and validate deletions or duplications. These methods are useful for targeted confirmation but may require prior knowledge of the variant’s approximate location and breakpoint structure.
  • Sanger sequencing can confirm the nucleotide sequence of PCR-amplified structural variant breakpoints. It is particularly useful for validating small insertions, deletions, and rearrangement junctions. Fluorescence in situ hybridization (FISH) uses fluorescently labelled DNA probes to detect the presence, absence, or chromosomal location of specific genomic regions. It is commonly used to investigate large deletions, duplications, and translocations. Karyotyping can reveal large chromosomal abnormalities, including aneuploidy and major rearrangements, while chromosomal microarray analysis and array comparative genomic hybridization (aCGH) can validate copy-number changes across the genome. Optical genome mapping provides information about large-scale genomic rearrangements using labelled DNA molecules and can complement sequencing-based approaches.
  • Long-read sequencing is increasingly important for validating complex structural variants. PacBio HiFi and Oxford Nanopore sequencing can generate reads that span large genomic regions, including repetitive sequences and rearrangement breakpoints. When a predicted variant is supported by multiple independent long reads with consistent alignment patterns, confidence in its structure can increase. Long-read genome assemblies can also help determine whether a complex rearrangement is correctly represented. Combining short-read sequencing, long-read sequencing, optical genome mapping, and targeted laboratory methods can provide more reliable evidence than relying on a single technology.
  • Structural variant visualization is the graphical representation of genomic alterations and their supporting evidence. Visualization helps researchers inspect sequencing alignments, identify breakpoint patterns, compare alternative genomic structures, and communicate results. It is especially important when analysing complex rearrangements that cannot be understood easily from a variant table alone. Visual inspection can reveal incorrect alignments, ambiguous breakpoints, overlapping variants, and unexpected relationships between genomic regions. It also helps researchers assess whether a predicted structural variant is supported by the underlying sequencing data.
  • The Integrative Genomics Viewer (IGV) is one of the most widely used tools for examining sequencing alignments and genomic variants. It can display BAM or CRAM alignment files, VCF variant files, reference genome sequences, gene annotations, and other genomic tracks. Researchers can inspect split reads, discordant read pairs, coverage changes, and breakpoint-spanning reads. IGV is particularly useful for evaluating deletions, insertions, duplications, and local rearrangements. Other genome browsers, including the UCSC Genome Browser and Ensembl Genome Browser, provide genomic context through gene annotations, regulatory elements, conservation data, and population variation resources.
  • Structural variants can also be visualized using specialized genomic visualization tools. Ribbon can display relationships between genomic regions and structural rearrangements, while JBrowse provides interactive genome browsing and annotation visualization. Circos is widely used to illustrate genome-wide relationships, chromosome rearrangements, translocations, and other large-scale genomic features using circular diagrams. D3-based visualization systems and other interactive platforms can support customized exploration of complex genomic data. For large structural variants and chromosome-scale rearrangements, karyotype plots and chromosome ideograms are useful for showing the location and distribution of genomic changes.
  • Copy-number variation is commonly visualized using coverage plots, chromosome-level profiles, and segmentation diagrams. A deletion generally produces reduced sequencing depth, whereas a duplication may produce increased coverage. Tools such as CNVnator and Control-FREEC can generate copy-number profiles that help identify regions of abnormal genomic dosage. In clinical and population genomics, copy-number plots can be combined with gene annotations to determine whether a variant affects coding regions, regulatory sequences, or multiple neighbouring genes. However, coverage differences must be interpreted carefully because sequencing depth, GC content, mapping quality, and library preparation can influence read counts.
  • Pangenome graphs provide another way to visualize structural variation. Unlike a conventional linear reference, a graph represents alternative genomic sequences as different paths through shared and variable regions. Tools such as VG and ODGI support graph manipulation and visualization, allowing researchers to explore sequence paths, alternative alleles, and structural differences among individuals. Pangenome visualization is particularly useful when a variant is absent from the conventional reference genome or when multiple alternative haplotypes need to be compared. It can also help investigate complex regions that are difficult to represent accurately using a single linear sequence.
  • After validation and visualization, structural variants must be interpreted in their biological or clinical context. Clinical interpretation involves evaluating whether a structural variant is likely to contribute to a disease, explain a patient’s phenotype, or influence disease susceptibility. The interpretation process considers variant type, size, genomic location, affected genes, inheritance pattern, population frequency, predicted functional consequences, previous disease associations, and available experimental evidence. A variant should not automatically be considered pathogenic simply because it affects a gene or produces a large genomic change. Its biological consequences and relationship with the individual’s clinical features must be carefully assessed.
  • An important step is identifying the genes and genomic elements affected by the structural variant. A deletion may remove an entire gene, part of a gene, or a regulatory region. A duplication may increase gene dosage or disrupt gene structure depending on its location and orientation. An inversion may interrupt a coding sequence or change the relationship between a gene and its regulatory elements. A translocation may produce a fusion gene or separate a gene from its normal regulatory environment. Structural variants can also affect enhancers, promoters, silencers, non-coding RNAs, and topologically associating domain (TAD) boundaries. Therefore, interpretation should consider both protein-coding and non-coding genomic regions.
  • The functional consequences of structural variants depend on the biological role of the affected genes and genomic regions. Deletions can cause loss of function or haploinsufficiency when one remaining gene copy cannot maintain normal activity. Duplications may produce increased gene dosage, although the relationship between copy number and expression is not always proportional. Structural variants affecting genes with dominant-negative or gain-of-function mechanisms may produce different effects from those involving simple loss of function. Variants affecting regulatory regions can alter gene expression without changing the coding sequence. Functional evidence from RNA sequencing, protein studies, gene expression assays, chromatin accessibility, and other molecular experiments can help clarify these consequences.
  • Inheritance analysis is essential when evaluating structural variants associated with inherited disorders. A variant may be inherited from an affected parent, inherited from an apparently unaffected parent, or arise de novo in the affected individual. A de novo variant is one that is not detected in the parents’ tested samples, although parental germline mosaicism may still be possible. The inheritance pattern can provide important evidence about pathogenicity. For example, a heterozygous deletion affecting a gene associated with a dominant disorder may be clinically relevant, while a heterozygous deletion in a recessive disease gene may require a second pathogenic variant on the other chromosome. Parental testing and haplotype analysis can help establish inheritance, phase, and the relationship between multiple variants.
  • Population frequency is another important factor in clinical interpretation. Structural variants that are common in healthy populations are generally less likely to cause rare, highly penetrant disorders, although exceptions exist. Population databases such as gnomAD SV, the Database of Genomic Variants (DGV), and other population-specific resources provide information about the occurrence and frequency of structural variants. Clinical resources such as ClinVar contain submitted interpretations of genetic variants and their relationships with diseases. DECIPHER provides information about genomic variants associated with developmental disorders and related phenotypes. These databases support interpretation, but their evidence must be reviewed carefully because classifications, sample sizes, population representation, and clinical annotations may vary.
  • Clinical interpretation of copy-number variants often uses standardized frameworks. The American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen) have developed guidelines for evaluating constitutional copy-number variants. These approaches consider evidence such as genomic content, dosage sensitivity, inheritance, population frequency, and phenotype consistency. Variants may be classified into categories such as pathogenic, likely pathogenic, uncertain significance, likely benign, and benign, depending on the applicable classification framework. These categories reflect the strength of available evidence rather than an absolute measure of biological effect. In particular, a variant of uncertain significance (VUS) should not be treated as a confirmed cause of disease without additional evidence.
  • Structural variant interpretation in cancer genomics requires a somewhat different approach from the interpretation of inherited variants. Tumours can acquire somatic structural changes during cancer development, including gene amplifications, deletions, translocations, inversions, and complex chromosomal rearrangements. The interpretation process considers the affected oncogenes, tumour suppressor genes, fusion genes, copy-number profiles, tumour type, and available treatment evidence. For example, a structural rearrangement producing an actionable gene fusion may help identify a potential targeted therapy. Tumour heterogeneity, subclonal variants, tumour purity, and differences between primary and metastatic samples must also be considered. Clinical decisions require validated diagnostic methods and evidence appropriate to the specific cancer and treatment.
  • The interpretation of structural variants in research and animal breeding shares several principles with clinical genetics but has different objectives. In animal genomics, variants may be evaluated for their association with production, reproduction, health, adaptation, and welfare traits. A deletion or duplication affecting a gene involved in growth, immunity, metabolism, or reproduction may influence an economically important phenotype. However, an association does not necessarily demonstrate causality. Researchers should consider population structure, linkage disequilibrium, breed composition, environmental effects, and genetic background. Validation in independent populations and functional evidence can help determine whether a structural variant is directly responsible for a trait or merely linked to another causal variant.
  • Bioinformatics pipelines support the complete process of validation, visualization, and interpretation. A typical workflow begins with quality control using FastQC and MultiQC, read preprocessing using fastp or Cutadapt, and alignment using BWA-MEM or minimap2. Structural variants are identified using callers such as Manta, DELLY, GRIDSS, Sniffles, or cuteSV, depending on the sequencing technology. Calls are compared and assessed using SURVIVOR and Truvari. Candidate variants are inspected in IGV and annotated using AnnotSV, Ensembl, and relevant clinical or population databases. Additional analyses may include copy-number profiling, gene expression analysis, functional enrichment, inheritance assessment, and phenotype matching. Reproducible pipelines, consistent reference genome versions, and documented quality-control criteria are essential for reliable results.
  • Several challenges remain in structural variant interpretation. Breakpoints may be difficult to resolve in repetitive regions, and different technologies may identify different representations of the same complex event. Standard variant formats may not fully describe complex rearrangements, while incomplete population databases can limit frequency-based interpretation. Clinical evidence may also be insufficient for rare or newly discovered variants. Furthermore, a structural variant may have different effects depending on tissue, developmental stage, genetic background, and environmental conditions. These limitations make independent validation, careful evidence assessment, and collaboration between bioinformaticians, geneticists, laboratory scientists, and clinicians particularly important.
  • Overall, validation, visualization, and clinical interpretation are essential for converting structural variant calls into reliable biological and medical knowledge. Validation establishes whether a predicted variant is genuine, visualization reveals its genomic structure and supporting evidence, and interpretation evaluates its functional and clinical significance. Integrating sequencing evidence, experimental methods, genome browsers, population databases, inheritance information, and functional studies provides a more complete understanding of structural variation. These approaches are important not only in clinical genetics and cancer research but also in evolutionary genomics, population studies, and animal breeding.
Author:

Leave a Reply

Your email address will not be published. Required fields are marked *